2022 American Society of Clinical Oncology (ASCO) Annual Meeting

TAKEDA ONCOLOGY SPONSORED ABSTRACTS

@TakedaOncology
Learn more at TakedaOncology.com
©2022 Takeda Pharmaceuticals U.S.A., Inc.
## Brentuximab Vedotin

**Abstract 7503**
First-line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1

**Session**
Oral Presentation
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Friday, June 3, 2022
1:00-4:00 PM CDT

**Abstract 10000**
Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus adriamycin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced stage classical Hodgkin lymphoma (cHL)

**Session**
Oral Presentation
Pediatric Oncology
Monday, June 6, 2022
3:00-6:00 PM CDT

## Brigatinib

**Abstract 9072**
Association of Depth of Target Lesion Response to Brigatinib With Outcomes in Patients With ALK Inhibitor-Naive ALK+ NSCLC in ALTA-1L

**Session**
Poster Presentation
Lung Cancer—Non-Small Cell Metastatic
Monday, June 6, 2022
8:00-11:00 AM CDT

**Abstract 9075**
Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial

**Session**
Poster Presentation
Lung Cancer—Non-Small Cell Metastatic
Monday, June 6, 2022
8:00-11:00 AM CDT

## Mobocertinib

**Abstract 9099**
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins+)-positive metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD

**Session**
Poster Presentation
Lung Cancer—Non-Small Cell Metastatic
Monday, June 6, 2022
8:00-11:00 AM CDT

**Abstract 9108**
Molecular Analysis of Circulating Tumor DNA (ctDNA) in Patients (Pts) With EGFR Exon 20 Insertion-Positive (ex20ins+) Advanced NSCLC Treated With Mobocertinib

**Session**
Poster Presentation
Lung Cancer—Non-Small Cell Metastatic
Monday, June 6, 2022
8:00-11:00 AM CDT

**Abstract 9115**
Matching-Adjusted Indirect Comparison (MAIC) of Mobocertinib vs Amivantamab in Patients with Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

**Session**
Poster Presentation
Lung Cancer—Non-Small Cell Metastatic
Monday, June 6, 2022
8:00-11:00 AM CDT
<table>
<thead>
<tr>
<th>ABSTRACT #</th>
<th>TITLE</th>
<th>SESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TPS2690</strong></td>
<td>Phase 1a/1b study design of the novel STING agonist immune stimulating antibody conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors</td>
<td>POSTER PRESENTATION Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022 8:00-11:00 AM CDT</td>
</tr>
<tr>
<td><strong>TPS2698</strong></td>
<td>TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design</td>
<td>POSTER PRESENTATION Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022 8:00-11:00 AM CDT</td>
</tr>
<tr>
<td><strong>9071</strong></td>
<td>Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors</td>
<td>ORAL PRESENTATION Developmental Therapeutics—Immunotherapy Saturday, June 4, 2022 1:15-4:15 PM CDT</td>
</tr>
<tr>
<td><strong>2506</strong></td>
<td>A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors</td>
<td>ORAL PRESENTATION Developmental Therapeutics—Immunotherapy Saturday, June 4, 2022 1:15-4:15 PM CDT</td>
</tr>
</tbody>
</table>